Ross Reife

Dr. Reife, a former executive in major global pharmaceutical companies and more recently a consultant for large, medium, and small pharmaceutical companies ( including interim Chief Medical Officer positions at companies like Neurovance, The Medicines Company, and SAGE Therapeutics), assists in Iliad’s development strategy pertaining to the expanded use of FRAT® assays in other neurological disease states. Dr. Reife brings a diverse medical background in both private/academic practice and as a senior-level strategy and operational executive spanning the R&D and commercial aspects of complex global pharmaceutical companies. Having extensive international market knowledge and on-the-ground cultural intelligence gained in Europe, Asia-Pacific, and Latin America building top-tier global teams that consistently achieve corporate strategic and financial objectives, Dr. Reife advises Iliad on a number of international strategic initiatives. A former Vice President of Global Medical Affairs at Wyeth Pharmaceuticals, Dr. Reife brings broad experience in developing in/out-licensing opportunities, M&A strategy/due diligence, designing relevant clinical studies, and alliance-based product development, regulatory compliance, and global new product launches. A Fellow of the American Academy of Neurology, Dr. Reife has obtained a BA from the University of Pennsylvania, an MBA from Columbia Business School, and an MD from Columbia University College of Physicians and Surgeons.